Aprea Therapeutics Inc (NAS:APRE)
$ 3.3 0.16 (5.1%) Market Cap: 17.07 Mil Enterprise Value: -11.72 Mil PE Ratio: 0 PB Ratio: 0.78 GF Score: 37/100

Aprea Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 07:50PM GMT
Release Date Price: $102.6 (-2.10%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan, and we're continuing the 2021 Healthcare Conference today with Aprea. I'm joined by the company's CEO, Chris Schade. (Operator Instructions)

So with that out of the way, let me turn it over to Chris.

Christian S. Schade
Aprea Therapeutics, Inc. - President, CEO & Chairman

Thanks, Jess, and happy new year. And on behalf of Aprea, I'd like to thank everyone for attending this afternoon and also to thank JPMorgan for the opportunity to present today.

If we move to Slide 2. Before beginning, I'd like to call everyone's attention to our forward-looking statements and refer you to our filings with the SEC, which explains the risks associated with our business.

Now moving forward to Slide 3. Aprea is the leader in developing novel anticancer therapeutics targeting the tumor suppressor protein, p53. Over the years, we've developed a wealth of preclinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot